758 results on '"*RICHTER syndrome"'
Search Results
2. Duvelisib and Nivolumab in Treating Patients With Richter Syndrome or Transformed Follicular Lymphoma
3. Evaluation of Treatment by Glofitamab in Combination With Rituximab or Obinutuzumab Plus CHOP in Patients With RIchter Syndrome (GLORIFY)
4. Nivolumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or High-Risk Untreated Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Richter Transformation
5. ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma
6. Testing the Addition of an Immunotherapy Agent, Atezolizumab, When Given With the Usual Chemo-Immunotherapy Drug Combination (Rituximab Plus Gemcitabine and Oxaliplatin) for Relapsed/Refractory (That Has Come Back or Not Responded to Treatment) Transformed Diffuse Large B-Cell Lymphoma
7. Venetoclax, Rituximab and Nivolumab in Combination for the Treatment of Richter's Transformation Arising From Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
8. Acalabrutinib, Venetoclax and Durvalumab for the Treatment of Richter Transformation From Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
9. Duvelisib and Venetoclax in Relapsed or Refractory CLL or SLL or RS
10. Copanlisib and Nivolumab in Treating Patients With Richter's Transformation or Transformed Indolent Non-Hodgkin Lymphoma
11. Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma
12. Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas
13. Blinatumomab after R-CHOP bridging therapy for patients with Richter transformation: a phase 2 multicentre trial.
14. MGA deletion leads to Richter's transformation by modulating mitochondrial OXPHOS.
15. Central nervous system involvement in chronic lymphocytic leukemia: a case report and review of literature.
16. Clonal dynamics of Richter transformation in chronic lymphocytic leukemia.
17. A Phase II Study of Venetoclax in Combination With Dose-adjusted EPOCH-R or R-CHOP for Patients With Richter's Syndrome
18. Ipilimumab, Ibrutinib, and Nivolumab for the Treatment of Chronic Lymphocytic Leukemia and Richter Transformation
19. A Study to Evaluate VIP152 in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia or Richter Syndrome
20. Polatuzumab Vedotin in Combination With Chemotherapy in Subjects With Richter's Transformation
21. Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma
22. (CHANT)Real World Study of Duvelisib in the Treatment of Non-Hodgkin's Lymphoma (NHL)
23. Mouse models of chronic lymphocytic leukemia and Richter transformation: what we have learnt and what we are missing.
24. Molecular Subtypes and the Role of TP53 in Diffuse Large B-Cell Lymphoma and Richter Syndrome.
25. Long‐term remission in a patient with relapsed Richter's transformation treated with CD19‐directed chimeric antigen‐receptor T‐cells after allogeneic stem cell transplantation.
26. Clinicopathologic findings of splenic marginal zone lymphoma with gallbladder involvement that progressed to diffuse large B-cell lymphoma in a dog.
27. Case report: 'Atypical Richter transformation from CLL-type monoclonal B-cell lymphocytosis into Burkitt lymphoma in a treatment naïve patient'.
28. The Diagnostic Performance of 2-[ 18 F]FDG PET/CT in Identifying Richter Transformation in Chronic Lymphocytic Leukemia: An Updated Systematic Review and Bivariate Meta-Analysis.
29. Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma
30. Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma or Relapsed or Refractory Richter Syndrome (MK-3475-170/KEYNOTE-170)
31. Lisocabtagene Maraleucel, Nivolumab and Ibrutinib for the Treatment of Richter's Transformation
32. Study of Ibrutinib & Obinutuzumab With/Without CHOP for Richter's Transformation or Richter's Syndrome Patients
33. BLINAtumomab After R-CHOP Debulking Therapy for Patients With Richter Transformation
34. Update on management of diffuse large B-cell lymphoma Richter's transformation.
35. A + AVD for Treatment of Hodgkin Lymphoma Variant of Richter's Transformation.
36. Richter transformation – retrospective treatment outcomes analysis in Polish Adult Leukemia Study Group.
37. Treatment of Double-Refractory Chronic Lymphocytic Leukemia—An Unmet Clinical Need.
38. 2-[ 18 F]-FDG PET/CT Semiquantitative and Radiomics Predictive Parameters of Richter's Transformation in CLL Patients.
39. Primary extranodal lymphomas: Five-year experience from a tertiary care center of North India.
40. Ibrutinib as first line therapy in chronic lymphocytic leukemia patients over 80 years old: A retrospective real‐life multicenter Italian cohort.
41. Genomic and Proteomic Study of Richter Syndrome (CGPSR) (CGPSR)
42. HMPL-760 Safety and Tolerability Study in Patients With Previously Treated CLL/SLL or NHL
43. A Trial of CHOP-R Therapy, With or Without Acalabrutinib, in Patients With Newly Diagnosed Richter's Syndrome (STELLAR)
44. Anisolymphocytosis: A clue for Richter transformation.
45. Study of Immunotherapy in Combination With Ublituximab and Umbralisib in Patients With Relapsed-refractory CLL or Richter's Transformation
46. An extranodal Richter's syndrome presenting with cardiac diffuse large B-cell lymphoma: a case report.
47. Response to therapy in Richter syndrome: a systematic review with meta-analysis of early clinical trials.
48. Therapeutic leukocytapheresis for leukostasis in chronic lymphocytic leukemia: A case report and literature review.
49. Cytogenomic features of Richter transformation.
50. Immunochemotherapy combined with novel agents for Richter syndrome: report of 3 cases.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.